Publication date: Dec 10, 2024
The coronavirus disease (COVID-19) pandemic has affected the epidemiology of respiratory syncytial virus (RSV) infection. This study assessed whether or not palivizumab prophylaxis was appropriate during the COVID-19 pandemic. This prospective study included children
Concepts | Keywords |
---|---|
Coronavirus | COVID-19 pandemic |
Covid | endemic |
Drugs | optimal prophylaxis |
Optimal | palivizumab |
Pandemic |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | respiratory syncytial virus infection |
disease | MESH | COVID-19 pandemic |
drug | DRUGBANK | Palivizumab |
pathway | KEGG | Coronavirus disease |
disease | MESH | infection |
Original Article
(Visited 1 times, 1 visits today)